MBX Biosciences, Inc. Common Stock (MBX) Interest Coverage Ratio: History & Chart

MBX Biosciences, Inc. Common Stock(MBX)

Biotechnology · Carmel, IN

$57.71-0.84 (-1.43%)

Delayed quote: Oct 6, 2026, 11:31 AM EDT

About MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Carmel, IN

63 employees

mbxbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Steve Hoerter

View full financials

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
MBX Biosciences, Inc. Common Stock (MBX)	$2.75B	N/A	N/A	N/A	N/A
Precigen, Inc. (PGEN)vs ›	$2.73B	-27.57x	N/A	N/A	N/A
AtriCure, Inc. (ATRC)vs ›	$2.78B	-0.59x	11.23x	11.23x	11.23x
Acadia Healthcare Company, Inc. (ACHC)vs ›	$2.70B	2.79x	3.64x	5.04x	5.11x
Aveanna Healthcare Holdings Inc. (AVAH)vs ›	$2.69B	1.89x	1.89x	0.94x	0.94x
Neogen Corporation (NEOG)vs ›	$2.69B	-0.37x	0.59x	204.00x	353.37x
TransMedics Group, Inc. (TMDX)vs ›	$2.82B	7.88x	5.24x	5.24x	5.24x
Beam Therapeutics Inc. (BEAM)vs ›	$2.64B	-8.77x	N/A	N/A	N/A
NewAmsterdam Pharma Company N.V. (NAMS)vs ›	$2.64B	N/A	N/A	N/A	N/A
Dyne Therapeutics, Inc. (DYN)vs ›	$2.89B	-75.61x	0.12x	0.12x	0.12x

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

MBX Biosciences, Inc. Common Stock (MBX)

$2.75B

N/A

Precigen, Inc. (PGEN)vs ›

$2.73B

-27.57x

N/A

AtriCure, Inc. (ATRC)vs ›